

Prof. UMUT KEFELİ

Personal Information

Email: umut.kefeli@kocaeli.edu.tr

Web: <https://avesis.kocaeli.edu.tr/umut.kefeli>

International Researcher IDs

ScholarID: z8sabHwAAAAJ

ORCID: 0000-0001-6126-5377

Publons / Web Of Science ResearcherID: V-6023-2018

Yoksis Researcher ID: 142246

Education Information

Post Doctorate of Medicine, Diğer (Kurumlar,hastaneler Vb.), Hastaneler, İstanbul Kartal Dr.Lütfi Kırdar Eğitim Ve Araştırma Hastanesi, Turkey 2009 - 2012

Expertise In Medicine, Marmara University, School Of Medicine, Turkey 2003 - 2008

Foreign Languages

English, B2 Upper Intermediate

Research Areas

Medicine, Internal Medicine Sciences, Internal Diseases , Oncology

Academic Titles / Tasks

Professor, Kocaeli University, Tıp Fakültesi, Dahili Tıp Bilimleri, 2019 - Continues

Associate Professor, Kocaeli University, Tıp Fakültesi, Dahili Tıp Bilimleri, 2016 - 2019

Assistant Professor, Kocaeli University, Tıp Fakültesi, Dahili Tıp Bilimleri, 2014 - 2016

Courses

ÜRİNER SİSTEM TÜMÖRLERİ, Undergraduate, 2016 - 2017

BAŞ ve BOYUN KANSERLERİ, Undergraduate, 2016 - 2017

KEMOTERAPİ İLAÇLARI, Undergraduate, 2016 - 2017

Published journal articles indexed by SCI, SSCI, and AHCI

1. Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study.

Majidova N., Seyyar M., Bayraktar D. I., Dinç G., İsgandarov E., Huseynov J., Yaşar A., Çelebi A., Sever N., Kocaaslan E.,

et al.

Biomolecules & biomedicine, vol.24, pp.1776-1784, 2024 (SCI-Expanded)

- II. **Expression of netrin-1 in uterine serous carcinoma and its association with prognosis**
Ucuncu Kefeli A., Yaprak Bayrak B., Betül Tuncce E., Vural Ç., Suyusal H. İ., Kefeli U., Aksu M. G.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, vol.166, no.3, pp.1337-1344, 2024 (SCI-Expanded)
- III. **Are the results of clinical trials in patients with NSCLC reflected in real life? The Registurk-Lung study**
Artac M., Yildirim M. E., Sumbul A. T., Ozturk A., Karadurmus N., Koral L., Demirci U., Arslan C., Gumus M., Kefeli U., et al.
JOURNAL OF CLINICAL ONCOLOGY, no.16, 2024 (SCI-Expanded)
- IV. **Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)**
YAŞAR H. A., Aktas B. Y., Ucar G., SEZGİN GÖKSU S., Bilgetekin I., Cakar B., Sakin A., Ates O., Basoglu T., Arslan C., et al.
Clinical Genitourinary Cancer, vol.22, no.3, 2024 (SCI-Expanded)
- V. **Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC**
Yildirim M. E., Karadurmus N., Okten I. N., TÜRK H. M., Urakci Z., Arslan C., Celik S., DANE F., ŞENDUR M. A. N., BİLİR C., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024 (SCI-Expanded)
- VI. **The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study**
Almuradova E., Seyyar M., Arak H., Tamer F., Kefeli U., Koca S., Sen E., Telli T. A., Karatas F., Gokmen I., et al.
INTERNATIONAL JOURNAL OF CANCER, vol.154, no.4, pp.692-700, 2024 (SCI-Expanded)
- VII. **The Prognostic Value of the HALP Score and Inflammatory Index in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Second-Generation Anti-Androgens**
BAKKAL TEMİ Y., Sahin E., KEFELİ U., ÇABUK D., UYGUN K.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.34, no.1, pp.28-34, 2024 (SCI-Expanded)
- VIII. **Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent ¹⁷⁷Lu-PSMA-617**
Şahin E., Kefeli U., Zorlu Ş., Seyyar M., Ozkorkmaz Akdag M., Can Sancı P., Karakayali A., Ucuncu Kefeli A., Bakkal Temi Y., Cabuk D., et al.
MEDICINE, vol.102, no.47, 2023 (SCI-Expanded)
- IX. **Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group**
Unal C., Azizy A., KARABULUT S., Tastekin D., AKYILDIZ A., YAŞAR S., YALÇIN Ş., ÇOBAN E., EVRENSEL T., Kalkan Z., et al.
ONCOLOGIST, vol.28, pp.875-884, 2023 (SCI-Expanded)
- X. **The Prognostic Utility of the Metastatic Lymph Node Ratio and the Number of Regional Lymph Nodes Removed from Patients with Small Bowel Adenocarcinomas**
Aydin D., KEFELİ U., Ozcelik M., Erdem G. U., ŞENDUR M. A. N., Yildirim M. E., Oven B. B., BİLİCİ A., Gumus M.
Medicina (Lithuania), vol.59, no.8, 2023 (SCI-Expanded)
- XI. **NUTRISCORE Compared to NRS-2002 for Detection of Malnutrition in Hospitalized Cancer Patients; A Cross Sectional Study**
Kefeli A., Seyyar M., ŞAHİN E., SARPER E. B., KEFELİ U.
Nutrition and Cancer, vol.75, no.8, pp.1619-1624, 2023 (SCI-Expanded)
- XII. **Surgical, pathological and clinical features of advanced colorectal cancers with metastasectomy. "Onco-Colon Turkey Registry" real-life data**
Karadurmus N., Yildirim E., Yalcin S., Gumus M., Bilir C., Cubukcu E., Simsek E. T., Arslan C., Dane F., Celik S., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.4, 2022 (SCI-Expanded)
- XIII. **Perceptions and acceptance of telemedicine among medical oncologists before and during the**

COVID-19 pandemic in Turkey

Sahin E., Kefeli U., Cabuk D., Ozden E., Cakmak Y., Kaypak M. A., Seyyar M., Uygun K.
SUPPORTIVE CARE IN CANCER, vol.29, no.12, pp.7497-7503, 2021 (SCI-Expanded)

- XIV. **Follicular lymphoma in a patient with splenosis: a case report**
Kefeli U., Mehtap Ö., Cakir Ö., Eruyar A. T., İsgoren S., Ucuncu K.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019 (SCI-Expanded)
- XV. **Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection.**
Aydin D., Sendur M., Kefeli U., Unal O., Tastekin D., Akyol M., Tanrikulu E., Ciltas A., Ustaalioglu B., Uysal M., et al.
Clinical colorectal cancer, vol.16, pp.220-227, 2017 (SCI-Expanded)
- XVI. **Netrin-1 in cancer: Potential biomarker and therapeutic target?**
Kefeli U., Ucuncu K., Cabuk D., Isik U., Sonkaya A., Acikgoz O., Ozden E., Uygun K.
TUMOR BIOLOGY, vol.39, no.4, 2017 (SCI-Expanded)
- XVII. **Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma.**
Aydin D., Sendur M., Kefeli U., Ustaalioglu B., Aydin O., Yildirim E., Isik D., Ozcelik M., Surmeli H., Oyman A., et al.
Clinical colorectal cancer, vol.16, pp.78-83, 2017 (SCI-Expanded)
- XVIII. **The value of plasma netrin-1 in non-small cell lung cancer patients as diagnostic and prognostic biomarker.**
Yıldırım M., Kefeli U., Aydın D., Sener N., Gümüş M.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol.37, pp.11903-11907, 2016 (SCI-Expanded)
- XIX. **Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology).**
Süner A., Aydın D., Hacıoğlu M., Doğu G., İmamoğlu G., Menekşe S., Pilancı K., Yazıcı Ö., Koca D., Karaağaç M., et al.
European review for medical and pharmacological sciences, vol.20, pp.1238-43, 2016 (SCI-Expanded)
- XX. **Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO).**
Aydin D., Sendur M., Kefeli U., Umut U., Tastekin D., Akyol M., Tanrikulu E., Ciltas A., Bala U., Sener D., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.21, pp.1242-1249, 2016 (SCI-Expanded)
- XXI. **Efficacy and Toxicity of Cisplatin and Capecitabine Combination in the First-Line Treatment of Patients with Advanced Gastric Cancer: A Multicenter Study by the Anatolian Society of Medical Oncology**
Ciltas A., Buyukberber S., Topcu T. O., Kucukoner M., Uyeturk U., Cihan S., Sendur M. A., Budakoglu B., Kefeli U., Yildiz R., et al.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGISİ, vol.26, no.2, pp.96-102, 2016 (SCI-Expanded)
- XXII. **Colorectal stenting for palliation and as a bridge to surgery: A 5-year follow-up study.**
Bayraktar B., Ozemir I., Kefeli U., Demiral G., Sagirolu J., Bayraktar O., Adali G., Ozcelik A., Tortum O.
World journal of gastroenterology, vol.21, pp.9373-9, 2015 (SCI-Expanded)
- XXIII. **Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy.**
Aydin D., Bilici A., Yavuzer D., Kefeli U., Tan A., Ercelep O., Mert A., Yuksel S., Ozcelik M., Isik D., et al.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol.17, pp.604-11, 2015 (SCI-Expanded)
- XXIV. **Clinical importance of discordance of hormone receptors and Her2/neu status after neoadjuvant chemotherapy in breast cancer.**
Basak O., Aker V., Bilici A., Gurleyik G., Erkol B., Kefeli U., Aliustaoglu M.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.19, pp.879-86, 2014 (SCI-Expanded)
- XXV. **Non-small cell lung cancer in women: A distinct entity?**
Kefeli U., Oven Ustaalioglu B. B., Yilmaz B., Aydin D., Sener N., Aliustaoglu M., Gumus M.
Gazi Medical Journal, vol.25, no.3, pp.92-96, 2014 (SCI-Expanded)
- XXVI. **Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line**

treatment: A retrospective multicenter experience.

Kefeli U, Benekli M, Sevinc A, Yildiz R, Kaplan M, Ciltas A, Balakan O, Isikdogan A, Coskun U, Dane F, et al. *Oncology letters*, vol.6, pp.605-611, 2013 (SCI-Expanded)

XXVII. **Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis.**

Korkmaz T, Seber S, Kefeli U, Sari E, Canhoroz M, Oven B, Yildirim E, Yasar N, Aydin D, Balvan O, et al. *Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico*, vol.15, pp.535-40, 2013 (SCI-Expanded)

XXVIII. **Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience.**

Kefeli U, Buyuberber S, Akyol M, Yildiz R, Kaplan M, Ciltas A, Sevinc A, Karaca H, Seker M, Ozdemir N, et al. *Hepato-gastroenterology*, vol.60, pp.647-52, 2013 (SCI-Expanded)

XXIX. **The importance of multifocal/multicentric tumor on the disease-free survival of breast cancer patients: single center experience.**

Ustaalioglu B, Bilici A, Kefeli U, Şeker M, Oncel M, Gezen C, Gumus M, Demirelli F. *American journal of clinical oncology*, vol.35, pp.580-6, 2012 (SCI-Expanded)

XXX. **Netrin-1 concentrations in patients with advanced gastric cancer and its relation with treatment.**

Kefeli U, Yildirim M, Aydin D, Madenci O, Yasar N, Sener N, Mert A, Yuksel S, Ercelep O, Korkmaz T, et al. *Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals*, vol.17, pp.663-7, 2012 (SCI-Expanded)

XXXI. **Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer.**

Eser M, Kement M, Balin S, Coskun C, Kefeli U, Gumus M, Altuntas Y, Kurt N, Mayadagli A. *World journal of surgical oncology*, vol.10, pp.180, 2012 (SCI-Expanded)

XXXII. **The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis**

Bozcuk H, Abali H, Coskun S, Aydiner A, Çinkaya A, Demirkazik A, Özet A, Yolcu A, Balkan A, Çavdar A, et al. *World Journal of Surgical Oncology*, vol.10, 2012 (SCI-Expanded)

XXXIII. **Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.**

Kaya A, Coskun U, Ozkan M, Sevinc A, Yilmaz A, Gumus M, Unal O, Ozdemir N, Alici S, Berk V, et al. *Onkologie*, vol.35, pp.576-80, 2012 (SCI-Expanded)

XXXIV. **Evaluation of Hodgkin lymphoma cases and determination of prognostic factors Hodgkin lenfoma olgulari{dotless}ni{dotless}n retrospektif deęerlendirilmesi ve prognostik faktörlerin saptanmasi{dotless}**

Şeker M, Meng A, Bilici A, Ustaalioglu B. B., Kefeli U, Özşeker N. I., Mayadaęli A., Salepci T., Gümüş M. *Turk Onkoloji Dergisi*, vol.26, no.3, pp.108-114, 2011 (SCI-Expanded)

XXXV. **Tissue and serum adiponectin levels in patients with gastric cancer: are there any correlations between adiponectin levels and histopathological variables?**

Seker M., Bilici A., Guler D., Ustaalioglu B., Gozu H., Erkal F., Sonmez B., Karaduman M., Kefeli U., Yildirim E., et al. *Hepato-gastroenterology*, vol.58, pp.1841-6, 2011 (SCI-Expanded)

XXXVI. **Prognostic factors in elderly patients with non-small cell lung cancer: a two-center experience**

Kefeli U, Kaya S, Ustaalioglu B, Bilici A, Kefeli A, Yildirim M, Seker M, Yilmaz B, Salepci T, Uygun K, et al. *MEDICAL ONCOLOGY*, vol.28, no.3, pp.661-666, 2011 (SCI-Expanded)

XXXVII. **F-18 FDG PET/CT imaging and bronchoscopic image of tracheal recurrence in patient with non-small-cell lung cancer.**

Oven U, Kefeli U, Bilici A, Ustaalioglu R, Seker M, Cinaral F, Dogusoy I. *Clinical nuclear medicine*, vol.36, pp.367-9, 2011 (SCI-Expanded)

XXXVIII. **A retrospective analysis of women's chances to become pregnant after completion of chemotherapy: a single center experience.**

Oven U, Bilici A, Kefeli U, Seker M, Salepci T, Unal O, Gumus M.

- Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.16, pp.349-52, 2011 (SCI-Expanded)
- XXXIX. **The role of PET-CT in the differential diagnosis of thymic mass after treatment of patients with lymphoma.**
Ustaalioglu B., Seker M., Bilici A., Canpolat N., Yildirim E., Kefeli U., Ustaalioglu R., Yilmaz B., Salepci T., Ozdemir N., et al.
Medical oncology (Northwood, London, England), vol.28, pp.258-64, 2011 (SCI-Expanded)
- XL. **A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy**
Kefeli U., Bilici A., Ustaalioglu B., Kefeli A., Yildirim M., Seker M., Gumus M.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, vol.283, no.2, pp.405-407, 2011 (SCI-Expanded)
- XLI. **The role of ¹⁸F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients' treatment decision making?**
Bilici A., Ustaalioglu B., Seker M., Kefeli U., Canpolat N., Tekinsoy B., Ozugur S., Gumus M.
European journal of nuclear medicine and molecular imaging, vol.38, pp.64-73, 2011 (SCI-Expanded)
- XLII. **Pulmonary toxicity in patients receiving docetaxel chemotherapy**
Yumuk P., Kefeli U., Ceyhan B., Dane F., Eroglu B., Gumus M., Cabuk D., Basaran G., Abacioglu U., Turhal N.
MEDICAL ONCOLOGY, vol.27, no.4, pp.1381-1388, 2010 (SCI-Expanded)
- XLIII. **Prognostic significance of perineural invasion in patients with gastric cancer who underwent curative resection.**
Bilici A., Seker M., Ustaalioglu B., Kefeli U., Yildirim E., Yavuzer D., Aydin F., Salepci T., Oncel M., Gumus M.
Annals of surgical oncology, vol.17, pp.2037-44, 2010 (SCI-Expanded)
- XLIV. **Is there a cut-off value for standardized uptake values in positron emission tomography for predicting response to treatment and survival in patients with advanced non-small cell lung cancer? Single center experience.**
Oven U., Gumus M., Bilici A., Seker M., Ustaalioglu R., Kefeli U., Salepci T., Canpolat N., Mayadagli A., Dogusoy I.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.15, pp.529-36, 2010 (SCI-Expanded)
- XLV. **Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma.**
Seker M., Ustaalioglu B., Bilici A., Yildirim M., Kefeli U., Barisik N., Tamer I., Gumus M.
Leukemia research, vol.34, 2010 (SCI-Expanded)
- XLVI. **Does the metastatic lymph node ratio influence the disease-free survival of patients with breast cancer: single-center experiences.**
Oven U., Bilici A., Kefeli U., Seker M., Yildirim E., Salepci T., Oncel M., Kement M., Gumus M.
Oncology, vol.79, pp.105-11, 2010 (SCI-Expanded)
- XLVII. **Is metastatic lymph node ratio superior to the number of metastatic lymph nodes to assess outcome and survival of gastric cancer?**
Bilici A., Ustaalioglu B., Gumus M., Seker M., Yilmaz B., Kefeli U., Yildirim E., Sonmez B., Salepci T., Kement M., et al.
Onkologie, vol.33, pp.101-5, 2010 (SCI-Expanded)
- XLVIII. **Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer.**
Kefeli U., Dane F., Yumuk P., Karamanoglu A., Iyikesici S., Basaran G., Turhal N.
European journal of cancer care, vol.18, pp.191-4, 2009 (SCI-Expanded)
- XLIX. **Psychosocial predictors of co-morbid somatization syndrome in dyspepsia**
Kuscu M., Imeryuz N., Celenk O., Asena E., Kiziltas S., Tanrikulu A., KEFELİ U.
JOURNAL OF PSYCHOSOMATIC RESEARCH, no.1, pp.35, 2005 (SCI-Expanded)

Articles Published in Other Journals

- I. **Can the Prognosis be Predicted by the Pretreatment Derived Neutrophil to Lymphocyte Ratio (dNLR) in Patients with Castration-Resistant Prostate Cancer Receiving Enzalutamide?**
TEMİ Y. B., ŞAHİN E., KEFELİ U., ÇABUK D., UYGUN K.

Kocaeli Tıp Dergisi, vol.13, no.1, pp.46-51, 2024 (Peer-Reviewed Journal)

- II. **Two Case of Breast Carcinoma Developing Reactive Axillary Lymphadenopathy After CoronaVac (Sinovac) Vaccine**
ŞAHİN E., ÇABUK D., YAPRAK BAYRAK B., ÇALIŞKAN F., ARSLAN A. S., ÖNESU Z., CAPA B., BAKKAL TEMİ Y., KEFELİ U., UYGUN K.
Open Access Journal of Oncology and Medicine, vol.5, no.3, pp.581-584, 2023 (Peer-Reviewed Journal)
- III. **RELATIONSHIPS OF BODY MASS INDEX WITH PROGNOSTIC FACTORS AND SURVIVAL IN ENDOMETRIAL CANCER**
YENİHAYAT E. M., KEFELİ U., ÇABUK D., IŞIK U., ÖZDEN E., ÇAKMAK Y., UYGUN K.
Acta medica nicomedia, vol.3, no.3, pp.94-99, 2020 (Peer-Reviewed Journal)
- IV. **Adjuvant Chemotherapy in Elderly Patients with Early-stage Non-small Cell Lung Cancer**
KEFELİ U., Kaymaz S., Aydın D., Isik D., ÇABUK D., Sonkaya A., Acikgoz O., IŞIK U., ÖZDEN E., UYGUN K.
BEZMIALEM SCIENCE, vol.7, no.4, pp.265-270, 2019 (ESCI)
- V. **Prognostic Factors for Operated Gallbladder Cancer.**
Oven U., Bilici A., Seker M., Kefeli U., Aydın D., Celik S., Demir T., Erkol B.
Journal of gastrointestinal cancer, vol.50, pp.451-457, 2019 (ESCI)
- VI. **Akciğer kanserinde sağkalımı etkileyen klinikopatolojik özellikler**
KEFELİ U., USTAALIOĞLU B. B., YILDIRIM M. E., ERKOL B., AYDIN D., ŞENER N., SONKAYA A., AÇIKGÖZ Ö.
MARMARA MEDICAL JOURNAL, vol.28, no.1, pp.21-26, 2015 (Scopus)
- VII. **Clinicopathological factors related to survival in lung cancer**
KEFELİ U., Oven Ustaalioglu B. B., Yildirim M. E., Erkol B., Aydın D., Sener N., Sonkaya A., Acikgoz O.
MARMARA MEDICAL JOURNAL, vol.28, no.1, pp.21-26, 2015 (ESCI)
- VIII. **İnflamatuvar Meme Kanseri Serimiz Tek Merkez Deneyimi**
Ustaalioglu B. B., BİLİCİ A., ŞEKER M., Salepçi T., Yıldırım E., KEFELİ U., Kement M., GÜMÜŞ M.
Acta Oncologica Turcica, vol.42, no.3, pp.93-99, 2009 (Peer-Reviewed Journal)
- IX. **NADİR BİR NAZOLAKRİMAL HEMANJİYOPERİSTOM OLGUSU**
Ustaalioglu B. B., ŞEKER M., BİLİCİ A., Erkol B., KEFELİ U., Yıldırım E., SÖNMEZ B., GÜMÜŞ M., Salepçi T.
Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi, vol.19, no.2, pp.93-96, 2008 (Peer-Reviewed Journal)

Refereed Congress / Symposium Publications in Proceedings

- I. **Metastatik Küçük Hücreli Dışı Akciğer Kanserli Hastaların Nivolumab İle Sağkalım Sonuçlarının Değerlendirilmesi**
BAKKAL TEMİ Y., KEFELİ U., UYGUN K.
Onkolojide Yenilikler Sempozyumu, Turkey, 27 - 29 October 2023
- II. **ABİRATERON VE ENZALUTAMİD: POST-DOSETAKSEL METASTATİK KASTRASYON DİRENÇLİ PROSTAT KANSERİ TEDAVİSİNDE BENZER ETKİNLİK, TEK MERKEZ DENEYİMİ**
Bakkal Temi Y., Kefeli U., Uygun K.
13th International Medicine and Health Sciences Researches Congress, Ankara, Turkey, 26 - 27 August 2023, pp.240
- III. **Abirateron ve Enzalutamid: Post-Dosetaksel Metastatik Kastrasyon Dirençli Prostat Kanseri Tedavisinde Benzer Etkinlik, Tek Merkez Deneyimi**
BAKKAL TEMİ Y., KEFELİ U., UYGUN K.
13. Uluslararası Tıp ve Sağlık Bilimleri Araştırmaları Kongresi, 26 - 27 August 2023
- IV. **MEME KANSERİNDE ATİPİK PREZENTASYON, OLGU SUNUMU**
ÖZKORKMAZ AKDAĞ M., SEYYAR M., CAN ŞANCI P., KARAKAYALI A., ŞAHİN E., BAKKAL TEMİ Y., ÇABUK D., KEFELİ U., UYGUN K.
26-30 NİSAN 2023 10. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Turkey, 26 - 30 April 2023
- V. **NADİR BİR VAKA: MEMENİN PRİMER NÖROENDOKRİN TÜMÖRÜ OLGUSU**
CAN ŞANCI P., KARAKAYALI A., ÖZKORKMAZ AKDAĞ M., SEYYAR M., ÇABUK D., KEFELİ U., BAKKAL TEMİ Y., UYGUN

K.

26-30 NİSAN 2023 10. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Turkey, 26 - 30 April 2023

VI. **TRASTUZUMAB DERUXTECAN'A BAĞLI GELİŞEN PNÖMONİT OLGUSU**

SEYYAR M., ŞAHİN E., CAN ŞANCI P., Özkorkmaz M. A., KARAKAYALI A., BAKKAL TEMİ Y., ÇABUK D., KEFELİ U., UYGUN K.

26-30 NİSAN 2023 10. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Turkey, 26 - 30 April 2023

VII. **MEME KANSERİNDE NADİR BİR PARANEOPLASTİK SENDROM, OLGU SUNUMU**

KARAKAYALI A., SEYYAR M., CAN ŞANCI P., ÖZKORKMAZ AKDAĞ M., ŞAHİN E., BAKKAL TEMİ Y., ÇABUK D., KEFELİ U., UYGUN K.

26-30 NİSAN 2023 10. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Ankara, Turkey, 26 - 30 April 2023

VIII. **Metastatik Renal Hücreli Karsinomda Birinci Seri Sunitinib Ve Pazopanibin Böbrek Fonksiyonlarına Etkisi**

BAKKAL TEMİ Y., ŞAHİN E., SEYYAR M., ÖZKORKMAZ AKDAĞ M., CAN ŞANCI P., KARAKAYALI A., KEFELİ U., ÇABUK D., UYGUN K.

13-16 NİSAN 2023 HEDEF KANSER 2023, Girne, Cyprus (Kkct), 13 - 16 April 2023

IX. **YASSI EPİTEL HÜCRELİ AKCİĞER KARSİNOMU OLGUSUNDA 12 YIL SONRA GELİŞEN KÜÇÜK HÜCRELİ KARSİNOM TRANSFORMASYONU**

Can Şancı P., Şahin E., Özkorkmaz Akdağ M., Karakayalı A., Seyyar M., Kaypak M. A., Çakmak Y., Çabuk D., Kefeli U., Uygun K.

9. Ulusal Akciğer Kanseri Kongresi, Antalya, Turkey, 16 - 19 December 2021, no.8, pp.90

X. **ADO-TRASTUZUMAB EMTANSİN TEDAVİSİ İLE UZUN SÜRELİ YANIT GÖRÜLEN BİR METASTATİK MEME KARSİNOMU OLGUSU**

Şahin E., Seyyar M., Kaypak M. A., Çakmak Y., Çabuk D., Kefeli U., Uygun K.

8. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Antalya, Turkey, 3 - 07 November 2021, no.207, pp.114

XI. **BRCA MUTASYONLU HASTALARIN KLİNİKOPATOLOJİK ÖZELLİKLERİ**

Şahin E., Çabuk D., Gökbayrak M., Çine N., Özden E., Seyyar M., Kaypak M. A., Çakmak Y., Işık U., Kefeli U., et al.

8. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Antalya, Turkey, 3 - 07 November 2021, no.187, pp.112

XII. **POSTMEENOPOZAL MEME KANSERİ HASTALARINDA ADJUVAN AROMATAZ İNHİBİTÖRLERİNİN VÜCUT KİTLE İNDEKSİNE GÖRE SAĞKALIMA ETKİSİ**

Şahin E., Şafak Ö., Çabuk D., Özden E., Işık U., Kefeli U., Uygun K.

8. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Antalya, Turkey, 3 - 07 November 2021, no.193, pp.113

XIII. **CORONAVAC (SİNOVAC) AŞISI SONRASINDA REAKTİF AKSİLLER LENFADENOPATİ GELİŞEN İKİ MEME KARSİNOMU OLGUSU**

Şahin E., Kaypak M. A., Yaprak Bayrak B., Çalışkan F., Arslan A. S., Seyyar M., Çakmak Y., Çabuk D., Kefeli U., Uygun K.

8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 3 - 07 November 2021, no.186, pp.111

XIV. **Geç tanı alan bir melanom olgusu**

ŞAHİN E., SEYYAR M., ŞİMŞEK E. E., ÖZÇELİK M., KAYPAK M. A., ÇAKMAK Y., BAKKAL TEMİ Y., KEFELİ U., ÇABUK D., UYGUN K.

13-17 EKİM 2021 5. ULUSAL İMMÜNÖTERAPİ VE ONKOLOJİ KONGRESİ, Antalya, Turkey, 13 - 17 October 2021

XV. **Geç tanı alan bir melanom olgusu**

Şahin E., Seyyar M., Elen Şimşek E., Özçelik M., Kaypak M. A., Çakmak Y., Çabuk D., Kefeli U., Uygun K.

5. Ulusal İmmünoterapi ve Onkoloji Kongresi, Antalya, Turkey, 13 - 17 October 2021, pp.10-11

XVI. **Metastatik küçük hücreli akciğer kanseri (khak) tanılı hastada atezolizumaba bağlı nadir bir yan etki: miyozit**

Şahin E., Seyyar M., Çabuk D., Yazıcı A., Tuncer F., Kaypak M. A., Çakmak Y., Kefeli U., Uygun K.

5. Ulusal İmmünoterapi ve Onkoloji Kongresi, Antalya, Turkey, 13 - 17 October 2021, pp.10-11

XVII. **Dabrafenib+trametinibe bağlı grade 4 nötropeni olgusu**

Seyyar M., Şahin E., Kaypak M. A., Çakmak Y., Kefeli U., Çabuk D., Uygun K.

5. Ulusal İmmünoterapi ve Onkoloji Kongresi, Antalya, Turkey, 13 - 17 October 2021, pp.20

XVIII. **Perioperative FLOT: Tolerability, pathological response rates, and the role of adjuvant phase**

Ozden E., Isik U., Cakmak Y., Uslu H., Tosun M., Sahin E., Kaypak M., Cabuk D., Kefeli U., Uygun K.

ESMO 22nd World Congress on Gastrointestinal Cancer, ELECTR NETWORK, 1 - 04 July 2020, vol.31

- XIX. The effect of chemotherapy on survival applied in the last term of life in cancer patients**
IŞIK U., Erol A., Cakmak Y., ÖZDEN E., KEFELİ U., ÇABUK D., UYGUN K., Simsek M.
10th Eurasian Hematology Oncology Congress, İstanbul, Turkey, 8 - 11 October 2019, vol.85
- XX. Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.**
Isik U., Kostek O., Demiray G., Dirican A., Simsek M., Buyuksimsek M., Ucar G., Gunaydin U. M., Sakalar T., Aliyev A., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- XXI. Erken evre Seminom'xxda Radyoterap mi, Kemoterapi mi?**
KEFELİ U.
2. Ulusal Ürogenital Kanserler Kongresi, Turkey, 11 - 14 October 2018
- XXII. Metastatik Renal Hücreli Karsinom Tek Merkez Deneyimi**
IŞIK U., ÖZDEN E., KEFELİ U., ÇABUK D., UYGUN K.
2. Ulusal Ürogenital Kanserler Kongresi, Turkey, 11 - 14 October 2018
- XXIII. PRİMER İNCE BARSAK MALİGN MELANOM OLGUSU**
IŞIK U., ÖZDEN E., KEFELİ U., ÇABUK D., UYGUN K.
7. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Turkey, 21 - 25 March 2018
- XXIV. J Gastrointest Cancer The prognostic factors for operated gallbladder cancer**
ÖVEN B. B., ŞEKER M., KEFELİ U., aydın d.
ESMO World Congress on Gastrointestinal Cancer 2017, 28 June - 01 July 2017
- XXV. Meme kanseri hastalarının klinik ve patolojik özelliklerinin retrospektif değerlendirilmesi ve sağkalım analizleri**
ÇABUK D., geçgel f., SONKAYA A., açığıöz ö., KEFELİ U., UYGUN K.
6. Türk Tıbbi Onkoloji Kongresi, Turkey, 23 March 2016
- XXVI. Akciğer kanseri olgularının klinik patolojik ve moleküler özellikleri ve sağkalım ilişkisi**
ÇABUK D., düNDAR e., SONKAYA A., KEFELİ U., UYGUN K.
6. Türk Tıbbi Onkoloji Kongresi, Turkey, 23 March 2016
- XXVII. Kliniğimizdeki mide kanserli hastaların klinik ve patolojik özelliklerinin retrospektif değerlendirilmesi**
ÇABUK D., kaymaz s., KEFELİ U., SONKAYA A., UYGUN K.
6. Türk Tıbbi Onkoloji Kongresi, Turkey, 23 March 2016
- XXVIII. KOLOREKTAL KANSER HASTALARINDA ADJUVAN XELOX ve FOLFOX REJİMLERİNİN RETROSPEKTİF KARŞILAŞTIRILMASI ATOD ÇALIŞMASI**
Uncu D., DANE F., Demir H., Menekşe S., Topçu Öztürk T., KEFELİ U., Pilancı Nur K., Baykara M., Ulaş A., Ustaalioglu B., et al.
12. Ulusal Tıbbi Onkoloji Kongresi, İzmir, Turkey, 16 - 20 September 2015
- XXIX. NÜKS BAZAL HÜCRE KANSERLİ BİR HASTADA VİSMODEGİB TEDAVİSİ İLE TAM CEVABIN PET BT İLE GÖSTERİLMESİ OLGU SUNUMU**
Kefeli Üçüncü A., KEFELİ U.
12. Ulusal Tıbbi Onkoloji Kongresi, İzmir, Turkey, 16 - 20 September 2015
- XXX. NÜKS BAZAL HÜCRELİ KANSERLİ BİR HASTADA VİSMODEGİB TEDAVİSİ İLE TAM CEVABIN FDG-PET/BT İLE GÖSTERİLMESİ OLGU SUNUMU**
ÜÇÜNCÜ KEFELİ A., KEFELİ U.
12. ULUSAL TIBBİ ONKOLOJİ KONGRESİ, Turkey, 16 September 2015
- XXXI. Altmış Beş Yaş Üstü Rezektabl Küçük Hücreli Dışı Akciğer Kanseri Hastalarında Adjuvan Tedavi Analizi**
KEFELİ U., Açığıöz Ö., SONKAYA A., ÇABUK D., Temel Gül A., ÖZBAY S., YILDIZ D. K., UYGUN K.
21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015
- XXXII. CLINICAL IMPORTANCE OF DISCORDANCE IN HORMONE RECEPTOR AND HER2/NEU STATUS AFTER**

NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER

Ustaalioglu B. B. O., Vardar F. A., Bilici A., Gurleyik G., Erkol B., Kefeli U.

39th ESMO Congress (ESMO), Madrid, Spain, 26 - 30 September 2014, vol.25

- XXXIII. **Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (MCRPC) after docetaxel chemotherapy: Multicentric experience of Anatolian Society of Medical Oncology**
Demirci U., Oflazoglu U., Kodaz H., Ciltas A., Kefeli U., Akyol M., Ozturk B., Geredell C., Seker M. M., Clhan S., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XXXIV. **COMPARISON OF SECOND LINE TREATMENT OUTCOMES BETWEEN SENSITIVE AND REFRACTORY SMALL CELL LUNG CANCER PATIENTS: A RETROSPECTIVE ANALYSIS**
Korkmaz T., Seber S., SARI E., Canhoroz M., Ustaalioglu B. O., Kefeli U., Balvan O., Gumus M., Yasar N., Turhal S. N.
37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna, Austria, 28 September - 02 October 2012, vol.23, pp.497-498
- XXXV. **PLASMA M30 AND M65 LEVELS IN PATIENTS WITH ADVANCED GASTRIC CANCER: IS THERE AN IMPACT ON SURVIVAL OF PATIENTS?**
Bilici A., Ustaalioglu B. B. O., Orcun A., Ercan S., Seker M., Kefeli U., Yilmaz B. E., Yildirim M. E., Gezen C., Gumus M.
35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, Italy, 8 - 12 October 2010, vol.21, pp.48
- XXXVI. **SERUM M30 AND M65 VALUES IN PATIENTS WITH ADVANCED STAGE NON-SMALL CELL LUNG CANCER COMPARED WITH HEALTHY CONTROL GROUP**
Ustaalioglu B. O., Bilici A., Ercan S., Orcun A., Seker M., Kefeli U., Ozkan A., Yilmaz B. E., Yildirim M. E., Gumus M.
35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, Italy, 8 - 12 October 2010, vol.21, pp.72-73
- XXXVII. **Is metastatic lymph node ratio superior to the number of metastatic lymph nodes to assess outcome and survival of gastric cancer**
BİLİCİ A., USTAALİOĞLU B., GÜMÜŞ M., ŞEKER M., ERKOL B., SÖNMEZ B., YILDIRIM M. E., KEFELİ U., SALEPÇİ T., KEMENT M.
2010 Gastrointestinal Cancers Symposium, United States Of America, 22 - 24 January 2010
- XXXVIII. **THE IMPORTANCE OF LIVER METASTASECTOMY IN METASTATIC COLORECTAL CANCER PATIENTS: SINGLE CENTER EXPERIENCES**
Ustaalioglu O. B., Seker M., Bilici A., Salepci T., Kefeli U., Oncel M., Yildirim E., Yilmaz B., Kement M., Gumus M.
12th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 30 June - 03 July 2010, vol.21, pp.68
- XXXIX. **Pulmonary toxicity in patients receiving docetaxel chemotherapy**
Kefeli U., YUMUK P. F., CEYHAN B., DANE F., Eroglu B., Cabuk D., Basaran G., Teomete M., Turhal N. S.
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27
- XL. **The prognostic impact of body mass index (BMI) in early breast cancer (BC) patients (pts).**
Iyikesici M., Kefeli U., Basaran G., Dane F., Ekenel M., Yumuk P., Turhal N.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23

Other Publications

- I. **Abiraterona Bağlı Gelişen Hipotiroidizm Olgusu**
Seyyar M., Şahin E., Kaypak M. A., Can Şancı P., Çabuk D., Kefeli U., Uygun K.
Presentation, pp.54, 2022
- II. **OKSALIPLATINE BAĞLI HIPERAMONYEMİK ENSEFALOPATI OLGUSU**
Kaypak M. A., Şahin E., Seyyar M., Karakayali A., Can Şancı P., Özkorkmaz Akdağ M., Çabuk D., Kefeli U., Uygun K.
Presentation, pp.189-190, 2022
- III. **TARAMA TESTİ İLE LOKAL İLERİ EVREDE SAPTANAN KOLONUN BÜYÜK HÜCRELİ NÖROENDOKRİN KARSINOM OLGUSU**
Can Şancı P., Seyyar M., Özkorkmaz Akdağ M., Karakayali A., Şahin E., Kaypak M. A., Çabuk D., Kefeli U., Uygun K.

Presentation, pp.153-154, 2022

IV. PAZOPANIBE BAĞLI HIPOGLISEMI OLGUSU

Findikli G., Seyyar M., Kaypak M. A., Şahin E., Can Şancı P., Çabuk D., Kefeli U., Uygun K.
Presentation, pp.224-225, 2022

V. CA 15-3 YÜKSEKLİĞİ İLE PROGRESYON SAPTANAN MEME KANSERİ OLGUSU

Seyyar M., Şahin E., Kaypak M. A., Can Şancı P., Çabuk D., Kefeli U., Uygun K.
Presentation, pp.232, 2022

VI. TANI KONULDUKTAN 2 YIL SONRA OPERE OLAN LUMINAL A MEME KANSERİ OLGUSU

Bırol K., Seyyar M., Şahin E., Can Şancı P., Çabuk D., Kefeli U., Uygun K.
Presentation, pp.228, 2022

Supported Projects

ÜÇÜNCÜ KEFELİ A., AKSU M. G., KEFELİ U., VURAL Ç., Suyusal H. İ., Project Supported by Higher Education Institutions, Uterin Seröz Kanserde Netrin1 Ekspresyonu Yeni Bir Biyomarker Olabilir Mi?, 2022 - 2023
KEFELİ U., ÖZGÜN Ö., Project Supported by Higher Education Institutions, KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERLİ HASTALARDA ADAM17 EKSPRESYONU VE SAĞKALIMLA İLİŞKİSİ, 2018 - 2020

Metrics

Publication: 104

Citation (WoS): 520

Citation (Scopus): 550

H-Index (WoS): 14

H-Index (Scopus): 15

Non Academic Experience

İSTANBUL GÖZTEPE EĞİTİM VE ARAŞTIRMA HASTANESİ
SÜREYYAPAŞA MESLEK HASTALIKLARI HASTANESİ